Medical Debt Suits Shift to Docs - Summary - MDSpire

Medical Debt Suits Shift to Docs

Physicians, dentists fill hospital gap

  • By

  • Noam N. Levey

  • Katy Golvala

  • Jenna Carlesso

  • April 20, 2026

  • 14 min

Share

Objective:

To investigate the shift in medical debt collection lawsuits from hospitals to non-hospital healthcare providers in Connecticut, highlighting its implications for patient care.

Approach:
    Key Findings:
    • Lawsuits by non-hospital providers now account for over 80% of medical debt cases in Connecticut.
    • This marks a significant shift from five years ago when hospital lawsuits dominated.
    • Most non-hospital providers are not bound by the same financial aid regulations as hospitals.
    • The shift raises concerns about patient care access and financial strain on families.
    Interpretation:

    The shift in lawsuits to non-hospital providers highlights a less regulated environment for medical debt collections, exacerbating financial burdens on patients and potentially limiting their access to necessary care.

    Limitations:
    • The study focuses solely on Connecticut and may not reflect national trends.
    • Data may not capture all instances of medical debt or the full impact on patients.
    • Potential bias in data collection methods may affect the findings.
    Conclusion:

    The trend of suing patients over medical debt by non-hospital providers raises urgent concerns about patient care access and financial strain on families.

    Sources:

Original Source(s)

Medical Debt Suits Shift to Docs

  • by Noam N. Levey, Katy Golvala, Jenna Carlesso

  • April 20, 2026

Related Content

Head-to-Head Trial in Relapsing MS

The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.

Increasing familial engagement in family violence services: a systematically conducted realist review of barriers and facilitators

FDA Approves Atacicept for IgA Nephropathy

The approval was based on reduced proteinuria, and an ongoing trial is required to determine whether atacicept slows long-term kidney function decline.